AKTX Akari Therapeutics, Plc
Akari Therapeutics, Plc (AKTX) is expected to report earnings on November 12, 2026, after the market close.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Akari Therapeutics, Plc
Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom.
Sector
Healthcare